Listed below are the current guidelines, provisional clinical opinions, endorsements, and updates in development. Topics prioritized for development by the Clinical Practice Guidelines Committee and Guideline Advisory Groups are listed by disease site. To submit a topic for consideration, take our survey. To learn more about the ASCO Guideline development process, access the Guideline Methodology page.

Guidelines/Provisional Clinical Opinions (PCOs)/Endorsements in Development

Breast Cancer

Gastrointestinal Cancer

  • Management of Localized and Locally Advanced Esophageal Adenocarcinoma and Squamous Cell Carcinoma
  • Systemic Therapy for Advanced Hepatocellular Carcinoma
  • Update: Stage II Colon Cancer
  • Update: Metastatic Pancreatic Cancer

Genitourinary Cancer

Gynecologic Cancer

  • Germline and Somatic Tumor Testing in Ovarian Cancer
  • PARP Inhibitors for Ovarian Cancer

Head and Neck Cancer

  • Unknown Primary in Head and Neck Cancer
  • Management of Salivary Gland Malignancy

Melanoma

  • Systemic Therapy for Melanoma

Neurooncology

  • Treatment of Patients with Brain Metastases
  • Therapy for Diffuse Astrocytic and Oligodendroglial Tumors

Resource Stratified

  • Treatment for Invasive Colorectal Cancer
  • Treatment of Ovarian Cancer

Supportive Care

Survivorship

Thoracic

Standards

  • Oral Dispensing Standards

Multi-Site

  • Somatic Genomic Panel Testing for Metastatic Disease

Guideline Priorities 2019-2020

Breast Cancer

Gastrointestinal Cancer

  • Systemic Therapy for Advanced Gastro-esophogeal Cancer
  • Treatment Options for Well-Differentiated Neuroendocrine Tumors
  • Management of Perioperative Gastric Cancer
  • Neoadjuvant and Adjuvant Therapy for Rectal Cancer, Including Watchful Waiting
  • Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Local Therapy for Metastatic Colorectal Cancer

Genitourinary Cancer

  • Management of Metastatic Renal Clear Cell Cancer
  • Management of Newly Diagnosed Clinical and Pathologic Node-Positive Prostate Cancer
  • Penile Cancer
  • Germline Genetic Testing for Prostate Cancer
  • Primary Tumor-Directed and Metastasis-Directed Local Therapy in Oligometastatic Prostate Cancer
  • Update: Muscle-Invasive and Metastatic Bladder Cancer

Gynecologic Cancer

  • First Platinum-Sensitive Ovarian Cancer Recurrence
  • Adjuvant Therapy for High Risk Endometrial Cancer Patients
  • Chemotherapy for Women With Advanced Stage Ovarian/Primary Peritoneal/Fallopian Tube Cancer Following Upfront Surgical Cytoreduction
  • Front-Line Maintenance in Ovarian Cancer
  • Update: Neoadjuvant Chemotherapy for Ovarian Cancer

Head and Neck Cancer

  • Use of Immune Checkpoint Inhibitors and PD-L1 Testing in Head and Neck Squamous Cell Carcinoma, Focusing on Recurrent/Metastatic Disease
  • Management of Locoregionally Recurrent Head and Neck Cancer Including Re-Irradiation
  • Use of Systemic Treatment in the Management of Advanced Thyroid Cancer
  • Pre-operative Decision-making and Its Impact on Function and Adjuvant Therapy in Transoral Endoscopic Head and Neck Surgery
  • Definitive Management of Locoregionally Advanced Nasopharyngeal Cancer

Multi-Site

  • Germline Genetic Testing
  • Adjuvant Therapy for Soft-Tissue Sarcoma
  • Management of Untreated Follicular Lymphoma
  • Chronic Lymphocytic Leukemia
  • Treatment of Oligometastatic Disease

Resource Stratified

Supportive Care

Survivorship

  • Exercise, Weight, and Obesity in Post-Treatment Cancer Survivors
  • Management of Lymphedema in Cancer Survivors
  • Management of Sleep Problems in Cancer Survivors
  • AYA Cancer Survivorship
  • Survivorship After Stem Cell Transplantation

Thoracic

  • Molecular Profiling for Predictive Biomarkers in Non-Small-Cell Lung Cancer
  • Systemic Therapy for Small Cell Lung Cancer
  • Management of Oligometastasis and Oligoprogressive Disease

Recently Published Guidelines